Eizen Joshua M sold AN2 Therapeutics ($ANTX) shares on the open market three times over the last year for a total of $28,176. His most recent sale occurred on January 6, 2026. These transactions rank 10,852nd out of 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.4 transactions per insider. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | D | Stock Option (right to buy) | 92000 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.30% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Stock Option (right to buy) | 50150 | $0.00 | 50,150.0000 | 30,276,230 | 9999.99% | 0.17% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | D | Stock Option (right to buy) | 50150 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.17% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Stock Option (right to buy) | 92000 | $0.00 | 92,000.0000 | 30,276,230 | 9999.99% | 0.30% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 30,276,230 | 9999.99% | 0.33% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Common Stock | 50000 | $0.00 | 207,499.0000 | 30,276,230 | 31.75% | 0.17% |
| Jan. 6, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | S | Common Stock | 6931 | $1.01 | 152,499.0000 | 30,276,230 | 4.35% | 0.02% |
| Jan. 5, 2026 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | S | Common Stock | 17923 | $1.00 | 159,430.0000 | 30,276,230 | 10.11% | 0.06% |
| Nov. 4, 2025 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | S | Common Stock | 2819 | $1.14 | 177,353.0000 | 30,276,230 | 1.56% | 0.01% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Common Stock | 58500 | $0.00 | 175,172.0000 | 29,828,227 | 50.14% | 0.20% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Stock Option (right to buy) | 117000 | $0.00 | 117,000.0000 | 29,828,227 | 9999.99% | 0.39% |
| Jan. 3, 2025 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | S | Common Stock | 9663 | $1.34 | 116,672.0000 | 29,828,227 | 7.65% | 0.03% |
| Nov. 4, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Common Stock | 31500 | $0.00 | 126,335.0000 | 29,841,169 | 33.22% | 0.11% |
| Nov. 4, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | See Remarks | A | Stock Option (right to buy) | 63000 | $0.00 | 63,000.0000 | 29,841,169 | 9999.99% | 0.21% |
| July 10, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | Chief Legal Officer | A | Common Stock | 60000 | $0.00 | 94,833.0000 | 23,600,107 | 172.25% | 0.25% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | Chief Legal Officer | A | Common Stock | 30000 | $0.00 | 32,447.0000 | 23,600,107 | 1225.99% | 0.13% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | Chief Legal Officer | A | Common Stock | 30000 | $0.00 | 32,447.0000 | 23,600,107 | 1225.99% | 0.13% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | Chief Legal Officer | A | Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 23,600,107 | 9999.99% | 0.25% |
| Feb. 15, 2023 | AN2 Therapeutics, Inc. | $ANTX | Eizen Joshua M | Chief Legal Officer | A | Stock Option (right to buy) | 50150 | $0.00 | 50,150.0000 | 0 | 9999.99% | 0.00% |